Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

An Ophthalmic Safety Study in Patients With Breast Cancer

NCT06767462 · View on ClinicalTrials.gov ↗

Study Summary

To assess ophthalmic health in parallel cohorts of patients with breast cancer

Study Locations (20)

Other

  • Research Site — Buenos Aires
  • Research Site — Buenos Aires
  • Research Site — CABA
  • Research Site — Córdoba
  • Research Site — San Miguel de Tucumán
  • Research Site — San Miguel de Tucumán
  • Research Site — Edegem
  • Research Site — Leuven

California

  • Research Site — La Jolla
  • Research Site — Palo Alto
  • Research Site — San Diego

Pennsylvania

  • Research Site — Clairton
  • Research Site — Pittsburgh

Iowa

  • Research Site — Iowa City

New York

  • Research Site — New York

North Carolina

  • Research Site — Winston-Salem

Ohio

  • Research Site — Cleveland

South Dakota

  • Research Site — Sioux Falls

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2025-03-04
Est. Completion 2027-07-06

Sponsor

AstraZeneca

1,053 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06767462

The ClinicalTrials.gov registry entry for NCT06767462 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,053 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Ophthalmic Safety in Patients With Breast Cancer appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06767462 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Other, California, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06767462 about?

NCT06767462 is a clinical study titled "An Ophthalmic Safety Study in Patients With Breast Cancer". To assess ophthalmic health in parallel cohorts of patients with breast cancer

What is the current status of trial NCT06767462?

This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2025-03-04. Estimated completion is 2027-07-06.

What conditions does trial NCT06767462 study?

This clinical trial studies the following conditions: Ophthalmic Safety in Patients With Breast Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT06767462?

This trial is sponsored by AstraZeneca, which has 1,053 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06767462 being conducted?

This trial has 20 study locations across California, Iowa, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial